基本信息
views: 40
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
I started my Bachelor's degree in Statistics at Razi University (ranked among top 2% students). My passion for numbers, problem solving and making sense of data in medical studies encouraged me to choose Biostatistics as my major field. So I continued my progress in Master of Biostatistics at Shahid Beheshty University of Medical Sciences (SBMU), and PhD of Biostatistics at Tarbiat Modares University. Now, I am working at SBMU (the second top medical University in Iran) as the Associate Professor with 12 years of experience in consulting and establishing successful community-based studies, clinical trials and cancer data analysis. Over the past ten years, I have teaching a variety of Biostatistics courses for medical students, and prepared Statistics and methodology workshops for students, researchers, medical doctors and faculty members as well, supervising (or consulting) MSc and PhD students in Biostatistics, Epidemiology and other discipline.
During my work at SBMU, teaching and consulting were not the only duties I have done. I also participated in clinical trials which conducted in faculty of Nursing and Midwifery and School of Pharmacy which lead to 15 publications. However, the coronavirus Pandemic pushed my skills in clinical trial to be flourished; definitely I was involved in the trials that targeting the drugs or therapy against COVID-19. Being member of SBMU Taskforce on The COVIFERON Trial was a big chance to experience of working under considerable pressure with a team of medical researchers in the worst outbreaks had ever seen in my country. The COVIFERON trials (that aimed to study the role of interferon therapy including two brands; Recigen and Ziferon) lead to five publications in high qualified Journals, finding out that Recigen was effective to reduce the rate of mortality in COVID-19 patients. We also studied the effect of Umifenovir (Arbidol brand) on moderate to severe COVID-19 patients in a randomized clinical trial. Today, I am still in touch with this professional group to do the rest of the trials with other therapies.
My experience with pharmaceutical industries was not limited to COVID-trials. I also implemented studies to estimate the direct medical care costs of chronic Hepatitis C infection, diagnosis and treatment costs of non-alcoholic Fatty liver disease, the cost of Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin in Hepatitis C patients, and economic burden of Celiac diseases, estimated in Purchasing Power Parity Dollar (PPP$). The results were published in qualified Journals, receiving considerable number of citations.
My research position involved working in a team of researchers from different disciplines. This experience significantly improved my ability to communicate to people outside of my field and as a Biostatistician, I learned the value of combining academic and clinical research. These academic researches resulted in more than 291 scientific papers (55 papers in collaboration with international colleagues), two national awards (Razi Research Festival and Abu Reyhan Biruni Research Festival) and I was invited as the oral presenter in national and international conferences.
During almost a decade of working as the head of Department of Health System Research (Research Institute for Gastroenterology and Liver Diseases, SBMU), I have had a strong interest in national cancer registry data to predict the trend of cancer burden, survival analysis for patients with colorectal or gastric cancers and modeling to predict the mortality rate of cancer patients according to clinicopathological factors (recently two projects have been done, jointly by Macquarie University, Australia) and analysis based on global burden of disease (GBD). Besides, designing and coordinating a Population-based study in Tehran metropolitan to estimate the burden of Functional bowel disorders in Iranian population, using Rome III criteria was one of my experience in public health study. The project almost included 22000 random selected people from Tehran, resulting in 8 highly qualified papers, with total of 436 citations up to now.
Research Interests
Papers共 365 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Molecular biology reportsno. 1 (2024): 127-127
Gohar Mohammadi,Mehdi Azizmohammad Looha,Mohammad Amin Pourhoseingholi,Mostafa Rezaei Tavirani,Samaneh Sohrabi,Amirali Zareie Shab Khaneh, Hassan Piri,Maryam Alaei, Naser Parvani, Iman Vakilzadeh,Sara Javadi, Zeynab Moradian Haft Cheshmeh,
Mohamad Amin Pourhoseingholi,Mehdi Azizmohammad Looha,Saba Ilkhani,Hamidreza Hatamabadi,Amir Sadeghi,Seyed Amir Ahmad Safavi-Naini,Kamran Heidari,Nazanin Taraghikhah, Mohammad Mahdi Fallah,Reyhaneh Kalantar, Nariman Naderi,Romina Esbati,
Journal of Clinical Virology Plusno. 2 (2024): 100180
FRONTIERS IN ARTIFICIAL INTELLIGENCE (2024): 1285037-1285037
Mohammad Reza Hatamnejad, Alireza Doostian, Setayesh Sotoudehnia korani,Mohamad Amin Pourhoseingholi
Shiraz E-Medical Journalno. 4 (2024)
Mohammad Eghbal Heidari,Seyed Sina Naghibi Irvani,Mohamad Amin Pourhoseingholi, Mona Maleki Takhtegahi, Rezvane Beyranvand,Hossein Mardanparvar,Hamed Hesami,Neda Ghavampour,Hossein Hatami
CURRENT MEDICINAL CHEMISTRY (2024)
INTERNATIONAL ENDODONTIC JOURNALno. 3 (2024): 305-314
The journal of Tehran Heart Centerno. 4 (2023): 261-268
Load More
Author Statistics
#Papers: 369
#Citation: 6675
H-Index: 38
G-Index: 62
Sociability: 7
Diversity: 4
Activity: 95
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn